Answers are grounded in this paper and cite their sources.
Case series reports limited targeted therapies for low tumor mutational burden in pediatric CNS tumors, suggesting implications for biomarker-guided treatment.
Background Novel immunotherapies and targeted therapies have revolutionized cancer care by targeting specific molecular pathways. PD-L1-targeted immunotherapies are widely used in various tumor types but are seldom employed in pediatric CNS tumors. Tumors with high tumor mutational burden (TMB) and PD-L1-targeted therapy have demonstrated promising response rates, but data on the implications of low TMB and PD-L1 presence in pediatric tumors remain scarce. This case series underscores the limited use of precision medicine in optimizing outcomes for pediatric CNS tumor patients with PD-L1 mutations. Methods We conducted a retrospective review of 160 patients from 4 academic institutions in New York from 2011-2023. Tumor and histopathologic data including TMB, tumor grade, progression, and survival outcomes were analyzed. Three patients with PD-L1 mutations who did not receive immunotherapy targeting that mutation were selected for case series review. Results The three pediatric patients with PD-L1 mutations that were not targeted had low TMB and high-grade tumors. Two patients survived, while one succumbed to progressive disease despite receiving surgery, chemotherapy, stem cell transplant, radiation, and targeted therapy. Of the two patients who experienced disease progression, both received targeted therapy alongside other treatments. The single patient who did not progress underwent surgical treatment alone. Conclusions The pediatric CNS tumors in this case series exhibit PD-L1 mutations and are associated with high-grade histology and low TMB, suggesting a unique and understudied tumor biology. While low TMB is relatively uncommon in PD-L1-mutated tumors, its presence in this series may explain the lack of PD-L1-targeted therapies. However, as PD-L1 inhibitors do not necessarily require high TMB for efficacy, this raises an important question: could immunotherapy have altered outcomes for these patients? Further research is essential to explore the role of PD-L1-targeted therapies in this subset and to integrate molecular biomarkers into therapeutic decisions for pediatric CNS tumors.
No takes yet. Share an insight, caveat, or question.
Horowitz et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: